Amgen Inc. said it has filed for U.S. approval of denosumab for the treatment of osteoporosis in post-menopausal women and for bone loss in breast and prostate cancer patients undergoing hormone reduction therapy.
Advertisement
FDA to consider osteoporosis drug
BUSINESS BRIEFING / PHARMACEUTICALS
FEATURED
MORE:
Advertisement
FROM THE ARCHIVES
- New osteoporosis drug shown to reduce fractures
August 12, 2009 - Exercise lifts cancer patients
June 19, 2006 - Merck Sued Over Fosamax Health Risks
April 11, 2006 - Asthma Steroids, Bone Loss Linked
September 27, 2001 - Treatment Options for Osteoporosis Patients
October 16, 2000
MORE STORIES ABOUT
